WO2009148230A3 - 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 - Google Patents

면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 Download PDF

Info

Publication number
WO2009148230A3
WO2009148230A3 PCT/KR2009/002715 KR2009002715W WO2009148230A3 WO 2009148230 A3 WO2009148230 A3 WO 2009148230A3 KR 2009002715 W KR2009002715 W KR 2009002715W WO 2009148230 A3 WO2009148230 A3 WO 2009148230A3
Authority
WO
WIPO (PCT)
Prior art keywords
peptide
preventing
composition containing
related diseases
treating hpv
Prior art date
Application number
PCT/KR2009/002715
Other languages
English (en)
French (fr)
Other versions
WO2009148230A2 (ko
Inventor
이경률
임종백
Original Assignee
바이오코아 주식회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 바이오코아 주식회사 filed Critical 바이오코아 주식회사
Publication of WO2009148230A2 publication Critical patent/WO2009148230A2/ko
Publication of WO2009148230A3 publication Critical patent/WO2009148230A3/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)

Abstract

본 발명은 면역성 펩타이드 및 그 펩타이드를 포함하는 HPV 관련 질환 예방 또는 치료용 조성물에 관한 것으로 더욱 상세하게는 HPV type 16의 E7 단백질 유래 E7 면역성 펩타이드 및 그 펩타이드를 포함하는 HPV 관련 질환 예방 또는 치료용 조성물에 관한 것이다.
PCT/KR2009/002715 2008-06-02 2009-05-22 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물 WO2009148230A2 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020080051832A KR20090125628A (ko) 2008-06-02 2008-06-02 면역성 펩타이드 및 그 펩타이드를 포함하는 ｈｐｖ 관련질환 예방 또는 치료용 조성물
KR10-2008-0051832 2008-06-02

Publications (2)

Publication Number Publication Date
WO2009148230A2 WO2009148230A2 (ko) 2009-12-10
WO2009148230A3 true WO2009148230A3 (ko) 2010-03-04

Family

ID=41398644

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2009/002715 WO2009148230A2 (ko) 2008-06-02 2009-05-22 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물

Country Status (2)

Country Link
KR (1) KR20090125628A (ko)
WO (1) WO2009148230A2 (ko)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10702598B2 (en) 2016-06-20 2020-07-07 Isa Pharmaceuticals B.V. Formulation of a peptide vaccine
AU2017338827B2 (en) 2016-10-03 2023-08-31 Juno Therapeutics, Inc. HPV-specific binding molecules
JP2020537515A (ja) 2017-10-03 2020-12-24 ジュノー セラピューティクス インコーポレイテッド Ｈｐｖ特異的結合分子
KR20210019993A (ko) 2018-04-05 2021-02-23 주노 쎄러퓨티크스 인코퍼레이티드 Τ 세포 수용체 및 이를 발현하는 조작된 세포

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BYEONG-SUN CHOI ET AL.: "Distinctive Distribution ofHPV16 E6 D25E and E7 N29S Intratypic Asian Variants in Korean Commercial Sex Workers.", JOURNAL OF MEDICAL VIROLOGY., vol. 79, no. 4, 2007, pages 426 - 430 *
DARJA KANDUC ET AL.: "NMR probing of in silico identification of anti-HPV 16 E7 mAb linear peptide epitope.", PEPTIDES., vol. 25, no. 2, 2004, pages 243 - 250 *
PAUL K. S. CHAN ET AL.: "Human Papillomavirus Type 16 Intratypic Variant Infection and Risk for Cervical Neoplasia in Southern China.", THE JOURNAL OF INFECTIOUS DISEASE., vol. 186, no. 5, 2002, pages 696 - 700 *
REINHARD KIRNBAUER ET AL.: "Efficient Self-Assembly of Human Papillomavirus Type 16 LI and L1-L2 into Virus-Like Particles.", JOURNAL OF VIROLOGY., vol. 67, no. 12, 1993, pages 6929 - 6936 *
VICTOR R. DEFILIPPIS ET AL.: "Evidence of Diversifying Selection in Human Papillomavirus Type 16 E6 But Not E7 Oncogenes.", JOURNAL OF MOLECULAR EVOLUTION., vol. 55, no. 4, 2002, pages 491 - 499 *

Also Published As

Publication number Publication date
KR20090125628A (ko) 2009-12-07
WO2009148230A2 (ko) 2009-12-10

Similar Documents

Publication Publication Date Title
WO2009059325A3 (en) Multitype hpv peptide compositions and methods for treatment or prevention of human papillomavirus infection
WO2009129246A3 (en) Compositions and methods for preparing and using same
WO2009137721A3 (en) Lysosomal targeting peptides and uses thereof
WO2007087384A3 (en) Methods for modulating mannose content of recombinant proteins
WO2010069532A8 (en) Antibodies against human angiopoietin 2
WO2006036916A3 (en) Rnai modulation of apob and uses thereof
EP2380591A3 (en) Vaccine peptide combinations against cat allergy
SG10201407640PA (en) Hepatitis b virus specific antibody and uses thereof
WO2009147248A3 (en) Amino acid sequences directed against envelope proteins of a virus and polypeptides comprising the same for the treatment of viral diseases
WO2008127364A3 (en) Antiviral compounds and use thereof
WO2009002159A3 (en) Intradermal hpv peptide vaccination
WO2007130616A3 (en) Polyamides for treating human papilloma virus
WO2009004593A3 (en) Processes for the preparation of epinephrine
WO2011157447A3 (en) Modified parvovirus having enhanced anti-tumour efficacy
WO2009051460A3 (en) Peptide coupled ascorbic acid derivatives
WO2009148229A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
IL210538A0 (en) Novel peptides for treating and preventing immune-related disorders, including treating and preventing infection by modulating innate immunuity
WO2010046061A3 (de) Kosmetische und/oder pharmazeutische zubereitungen
WO2012075015A3 (en) Oral metronidazole pharmaceutical compositions
WO2007079312A3 (en) Compositions and methods for treating actin-mediated medical conditions
WO2011098778A3 (en) Peptides for vaccines against birch allergy
WO2009148230A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
WO2010057242A3 (de) Vakzin
WO2009120022A3 (ko) 면역성 펩타이드 및 그 펩타이드를 포함하는 hpv 관련 질환 예방 또는 치료용 조성물
WO2008033556A3 (en) High pressure treatment of proteins for reduced immunogenicity

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 09758483

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09758483

Country of ref document: EP

Kind code of ref document: A2